Tau Self-Association Inhibitor Achieved First in Human Dosing

February 3, 2023

Fox Chase Therapeutics Discovery Inc (formerly known as Fox Chase Chemical Diversity Center) Announces That a Tau Self-Association Inhibitor Designed and Prepared in its Laboratories Has Achieved First in Human Dosing

Doylestown, PA. February 3, 2023 – FCTDI (formerly known as FCCDC) is pleased to announce that a tau self-association inhibitor designed and prepared in its laboratories under contract with Oligomerix, Inc. has achieved First in Human dosing as posted See the official press release here.